Background and Objectives Bupropion is an atypical antidepressant and smoking cessation aid associated with wide intersubject variability. This study compared the formation kinetics of three phase I metabolites (hydroxybupropion, threohydrobupropion, and erythrohydrobupropion) in human, marmoset, rat, and mouse liver microsomes. The objective was to establish suitability and limitations for subsequent use of nonclinical species to model bupropion central nervous system (CNS) disposition in humans. Methods Hepatic microsomal incubations were conducted separately for the R-and S-bupropion enantiomers, and the formation of enantiomer-specific metabolites was determined using LC-MS/MS. Intrinsic formation clearance (CL int ) of metabolites across the four species was determined from the formation rate versus substrate concentration relationship. Results The total clearance of S-bupropion was higher than that of R-bupropion in monkey and human liver microsomes. The contribution of hydroxybupropion to the total racemic bupropion clearance was 38%, 62%, 17%, and 96% in human, monkey, rat, and mouse, respectively. In the same species order, threohydrobupropion contributed 53%, 23%, 17%, and 3%, and erythrohydrobupropion contributed 9%, 14%, 66%, and 1.3%, respectively, to racemic bupropion clearance. Conclusion The results demonstrate that phase I metabolism in monkeys best approximates that observed in humans, and support the preferred use of this species to investigate possible pharmacokinetic factors that influence the CNS disposition of bupropion and contribute to its high intersubject variability.
Introduction
Bupropion has been marketed as Wellbutrin ® for the management of depression and as Zyban ® , a smoking cessation aid, since the early 1990s [1] . Its recent approval by the U.S. FDA for use in combination with naltrexone, Contrave ® for obesity and a recent positive outcome in clinical trials for attention-deficit/hyperactivity disorder (ADHD) further exemplify the multifaceted therapeutic potential of this drug [2] [3] [4] [5] [6] . However, despite being a biopharmaceutical classification system (BCS) class I drug, the failure of generic bupropion to meet U.S. FDA bioequivalence standards has drawn attention to the problem of interpatient variability in its clinical response [7] [8] [9] [10] [11] [12] [13] [14] [15] . This is of concern due to its high propensity to induce seizures and other side effects [7, 10, 11, [16] [17] [18] [19] . With over 40 million patients worldwide prescribed bupropion [1] , understanding causes of intersubject variability is critical. Variability in the metabolism of bupropion is considered to be chiefly responsible for the variability in its response [10, [12] [13] [14] [20] [21] [22] .
The disposition and pharmacology of bupropion are complex, since both bupropion and its metabolites have diverse pharmacokinetic and pharmacodynamic profiles [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . Though bupropion is clinically administered as a racemate, plasma exposure of R-bupropion and its metabolites are reported to be higher than exposure to the S enantiomer and its metabolites [20] [21] [22] . Both enantiomers are reported to undergo stereoselective phase I and II metabolism mediated by multiple enzymes [20, 23, 28] . In vitro and in vivo studies indicate that stereoselective phase I and II metabolic pathways contribute to the observed differences in the plasma profiles of bupropion enantiomers and their metabolites [20] [21] [22] [23] . Furthermore, several of the isoforms of these metabolizing enzymes and pharmacological targets are polymorphic [31, 32] , making this also a potential factor contributing to inter-subject variability.
Despite lower plasma exposure of S,S-hydroxybupropion than R,R-hydroxybupropion and bupropion enantiomers, in vitro studies [25, 26] and rodent behavioral studies [25, 26, 33, 34] indicate that this metabolite plays an important role in the efficacy of the marketed product, both as an antidepressant and smoking cessation aid. However, attempts to bring S,S-hydroxybupropion or its structural analogs to the clinic have met with limited success [35, 36] , implying that other metabolites may also contribute to bupropion's overall therapeutic activity. This argument is strengthened by findings from studies that attribute the pharmacological activity of bupropion at several targets (dopamine and norepinephrine transporter inhibition, and agonist and/or antagonist effects at multiple central nicotinic receptors) to reductive metabolites [33, [37] [38] [39] .
Previous studies of other centrally acting drugs have suggested that, despite lower expression of cytochrome P450 (CYPs) in the brain than in the liver, local metabolism by CYPs may also influence exposure in brain, and that this might contribute to inter-individual variability in response [40] [41] [42] [43] [44] [45] [46] . The possibility that stereoselective disposition in the brain is a potential source of intersubject variability in response to bupropion is supported by rodent studies demonstrating nicotine-mediated induction of brain CYP2B [47] . Interestingly, metabolite-to-bupropion exposure ratios in plasma were different from those observed in rat brain [24] and human cerebrospinal fluid (CSF) [8] , suggesting that plasma may not be an adequate indicator of brain exposure. One approach to understanding stereoselective bupropion disposition in the brain as a potential source of the intersubject variability in response to bupropion would be to conduct plasma and brain pharmacokinetic studies in surrogate nonclinical species. In vitro and in vivo studies conducted in mice, rats, and monkeys have not comprehensively evaluated relative systemic exposure and thus the potential individual pharmacologic contributions of the R-and S-bupropion enantiomers and their metabolites [24, 25, 29, [48] [49] [50] [51] .
The aim of the present work was therefore to compare the stereoselective phase I metabolism of bupropion in liver microsomes in three animal species with that in humans. Ideally, this would enable selection of the animal species with stereoselective systemic metabolism of bupropion that most closely resembles that in humans. This animal species could then be used for in vivo experiments to measure bupropion enantiomer and corresponding metabolite diastereomer exposure in brain interstitial fluid using microdialysis. The resulting comprehensive exposure profile in brain interstitial fluid, which bathes the multiple targets postulated to contribute to bupropion efficacy, would ultimately support translational physiologic-based pharmacokinetic modeling and simulation to predict the contributions of the bupropion enantiomers and metabolite diastereomers to target engagement in the human brain-as has already been done for atomoxetine and duloxetine [52, 53] . It is hoped that these efforts will aid prediction of the full gamut of bupropion and metabolite disposition in the CNS, thus further our understanding of factors contributing to the variability in bupropion's effectiveness for treating depression, weight loss and as an adjunctive therapy in smoking cessation programs.
Materials and Methods

Materials
R-bupropion, S-bupropion, R,R-hydroxybupropion, S,S-
hydroxybupropion, racemic (rac)-threohydrobupropion, rac-erythrohydrobupropion, and acetaminophen were purchased from Toronto Research Chemicals (Toronto, ON, Canada). Nicotinamide adenine dinucleotide phosphate (NADPH) was purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). Magnesium chloride heptahydrate, potassium phosphate dibasic anhydrous, potassium phosphate monobasic, HPLC-grade methanol, and HPLCgrade acetonitrile were purchased from Fisher Scientific (Fair Lawn, NJ, USA). Pooled human liver microsomes, rat (adult male Sprague-Dawley) liver microsomes, and mouse (female CD-1) liver microsomes were purchased from Corning (Woburn, MA, USA). Monkey (adult male marmoset) liver microsomes were purchased from BD Gentest (Woburn, MA, USA).
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Method Development and Validation
Standard Curve and Quality Control Samples
Individual standard stock solutions (1 mg/mL) of R-bupropion, S-bupropion, S,S-hydroxybupropion, R,R-hydroxybupropion, rac-threohydrobupropion, and rac-erythrohydrobupropion were prepared in 2-mL polypropylene tubes by dissolving the compounds in methanol. As reported by Masters et al. [54] , such stock solutions have been found to be stable for 48 h. All solutions were stored at − 20 °C. On the day of an analysis, standards were prepared from the standard stock solutions. Standard curves for R-bupropion, R,R-hydroxybupropion, rac-threohydrobupropion, and racerythrohydrobupropion included data for the following concentrations: 0.025, 0.05, 0.20, 1.0, 5.0, 20, 100, and 500 ng/ mL. Those for S-bupropion, S,S-hydroxybupropion, rac-threohydrobupropion, and rac-erythrohydrobupropion included data for the following concentrations: 0.050, 0.25, 0.50, 1.0, 2.5, 5.0, and 10 ng/mL. The smaller concentration range used for S-bupropion and its metabolites was in response to observations from R-bupropion incubations in which metabolite concentrations did not exceed 10 ng/mL. Quality control (QC) samples were run in triplicate along with the standards to generate statistical data for assay accuracy and precision. QC samples had the following concentrations for R-bupropion, R,R-hydroxybupropion, rac-threohydrobupropion, and rac-erythrohydrobupropion: 1 ng/mL (low QC), 100 ng/mL (medium QC), and 500 ng/mL (high QC). For S-bupropion and S,S-hydroxybupropion, QC samples had the following concentrations: 0.10 ng/mL (low QC), 1.0 ng/mL (medium QC), and 10 ng/mL (high QC). Samples were run in a matrix consisting of a 1:4 phosphate buffer (pH 7.4):acetonitrile mixture with the addition of 0.1% formic acid and 100 nM acetaminophen (APAP) used as the internal standard. The standards and QC samples also contained 0.5 mg/ mL of hepatic microsomes from the relevant species to ensure consistency with the incubated sample preparations.
HPLC Conditions
Chromatography was performed using a Phenomenex KINTEX Luna ® (150 × 4.6 mm) 3.0-micron C18 column. Achiral chromatography conditions were used; this was possible because separate incubations were conducted with the individual bupropion enantiomers. Injection volume was held constant at 3 μL, and the mobile phase was delivered as a gradient with a constant flow rate of 0.5 mL/min. A binary mobile phase was employed that consisted of (A) an aqueous solution of 20 mM ammonium acetate plus 0.1% ammonium hydroxide (pH 5.7) and (B) methanol. The mobile phase was delivered as a gradient that began at 55% A and decreased to 45% A over 8 min. From 8 to 12 min, mobile phase A was decreased to 35%. From 12 to 14 min, mobile phase A was decreased from 35 to 25%. Next, mobile phase A was decreased from 25 to 10% over 2 min, and was held for 2 min. From 18 to 18.1 min, mobile phase A was increased from 10 to 55%, which was maintained for 4.4 min to re-equilibrate the column for the next run.
Triple-Quadrupole Mass Spectrometer (QqQ/MS) Conditions
An Agilent 6460 with Agilent Jet Stream (AJS) thermal focusing technology was used to identify analytes following LC separation. A multiple reaction monitoring (MRM) scanning method was used because of its sensitivity. The optimal parameters for the AJS-ESI source were the following: gas temperature (320 °C); nebulizer pressure (45 psi); sheath gas temperature (400 °C); sheath gas flow (11 L/min); capillary voltage (4000 V); and nozzle voltage (500 V). Bupropion and its metabolites were detected by positive ion electrospray ionization (ESI) using the mass transitions summarized in Table S1 of the Electronic supplementary material (ESM). As shown in the table, the mass transitions of S-bupropion and its derived metabolites were identical to those of the respective stereoisomers of R-bupropion and its derived metabolites.
Assay Performance
Calibration curves were analyzed by least squares regression analysis using the Agilent MassHunter Workstation TM quantitative software. The model used for each calibration curve was linear with a weighting of 1/y to optimize each analyte. The accuracy and precision for each analyte were determined based on the QC concentrations. Intraassay precision and accuracy were calculated from three samples per QC concentration. Samples from each species were run on a single day, thus obviating the need to evaluate interassay accuracy and precision. Accuracy is expressed as the percentage of the nominal concentration, and precision is considered to be the percent coefficient of variation (%CV).
Microsomal Incubations
Microsomal incubation mixtures consisted of 100 mM potassium phosphate buffer pH 7.4, 5 mM magnesium chloride (MgCl 2 ), 0.5 mg/mL hepatic microsomes of the species of interest (human, monkey, rat, or mouse), and substrate (R-or S-bupropion). Based on prior time-dependent experiments for each species, 7 min was chosen as the incubation time. At this time and microsomal protein concentration, there was no observable substrate depletion; furthermore, formation of metabolites was linear with respect to time. Formation rate of the metabolite across the four species was determined at six different substrate concentrations ranging from 0.4 to 10 µM. This range is identical to that used by Sager et al. [28] when employing human liver S9 fractions, and it encompasses clinically relevant bupropion concentrations [21] . It also encompasses the range of racemic bupropion and S,S-hydroxybupropion concentrations observed in rats following a 10 mg/kg dose of racemic bupropion or 2 mg/kg S,S-hydroxybupropion, which were maximal at 1 µM and 3 µM, respectively [48] . Because similar systemic concentrations would be targeted for any of the three nonclinical species potentially used to evaluate the in vivo plasma and brain pharmacokinetics of bupropion enantiomers and metabolites, the same concentration range used in the human incubations was also used for the nonclinical species. Reactions were initiated by adding NADPH (1 mM) following 5 min of preincubation at 37 °C in a water bath. The total incubation volume after addition of NADPH was 100 µL. All concentrations stated above represent the final concentration in the 100-µL incubation volume. The reaction was stopped with 400 µL of ice-cold acetonitrile containing 0.1% (v/v) formic acid and acetaminophen (final internal standard concentration in 500 µL was 0.1 µM). After stopping the reaction, all samples were centrifuged for 15 min at 3000×g, 4 °C and the supernatant was then transferred to microcentrifuge tubes and stored at − 80 °C until analysis. Incubations were performed in triplicate and controls (no NADPH) were run in parallel. Since S-and R-4′-hydroxybupropion are reported to be minor metabolites in humans (contributing < 10% to the overall bupropion clearance) [28] , and with no reported pharmacological activity or commercially available standards, these metabolites were not evaluated. As shown in Fig. 1 , a specific threohydrobupropion (S,S-vs. R,R-) or erythohydrobupropion (R,S-vs S,R-) metabolite is formed when incubations are conducted with a specific enantiomer. This obviated the need to correct standard concentrations of the racemic mixture of these two metabolite types (threo and erythro) for the individual diastereomers when calculating unknown concentrations of these metabolites from the incubations.
The formation rate of a metabolite was plotted against substrate concentration and fitted via linear or nonlinear regression models in JMP ® , version 13.2.0 (SAS Institute Inc., Cary, NC, USA) and GraphPad Prism version 6.00 for Windows (GraphPad Software, La Jolla, CA, USA). Final model selection was guided by the precision of the parameter estimates, objective function, and an examination of the goodness-of-fit plots. When the metabolite formation kinetics were linear, the intrinsic clearance (CL int ) was calculated from the slope of the formation rate (v) versus substrate concentration (S) plots. When nonlinear kinetics were observed, CL int was calculated as the ratio of V max to K m based on the Michaelis-Menten equation (1) , which reduces to concentration-independent kinetics when [S] ≪ K m :
The intrinsic clearance (CL int ) was scaled to the intrinsic hepatic clearance (CL int,H ) using the equation below for the four species. Values of the two ratios that are specific to each species are summarized in the respective table legends.
Results
LC-MS/MS Method Development and Validation
C h r o m a t o g r a p h i c s e p a r a t i o n o f b u p r o p i o n (R-or S-), hydroxybupropion (S,S-or R,R-),
rac-erythrohydrobupropion, and rac-threohydrobupropion was successfully achieved using a Phenomenex KINTEX Luna ® (150 × 4.6 mm) 3.0-micron C18 column. Figure S1 in the ESM shows a chromatogram for S-bupropion and its derived metabolites. As achiral conditions were used, the developed method was employed for both R-and S-bupropion and their corresponding metabolites, and was found to be reproducible for the four animal species. Bupropion enantiomer inversion was minimized by using a short incubation time of 7 min, which is consistent with its reported half-life in plasma, 1.3 h [28] .
Method performance is summarized in Table S2 of the ESM. The calibration curves generated were linear for all analytes, and r 2 values were generally ≥ 0.99. Assay accuracy and precision were ≤ 20% for all QC samples. Tables 1, 2 , 3, and 4 summarize the kinetics of R-and S-bupropion phase I metabolism in human, marmoset, rat, and mouse liver microsomes, respectively. The formation clearance (CL int ) of each metabolite was estimated from the relationship between formation rate and substrate concentration (in the range 0.4-10 µM). This relationship is summarized for each of the above species in Figs. 2, 3 , 4, and 5, respectively. In marmoset, a linear relationship was observed for all six metabolites; in the mouse, saturable kinetics was observed for all six metabolites. Human and rat formation kinetics were mixed linear and nonlinear. Table 5 summarizes the V max and K m estimates in cases where nonlinear kinetics were observed. In such cases, CL int represents the ratio V max /K m , which would apply to conditions in which the substrate concentration is ≪ K m according to Eq. 1.
Microsomal Incubation Kinetics
Characterization of Bupropion Metabolism in Human Liver Microsomes (HLMs)
The total CL int of S-bupropion was 5.6-fold higher than that of R-bupropion ( Table 1 ). The various fractions of measured metabolites that contribute to the total CL int of each bupropion enantiomer are also summarized in Table 1 . R,Rhydroxybupropion was found to be the major metabolite of R-bupropion, while S,S-threohydrobupropion was the major metabolite of S-bupropion. Each of the three metabolites derived from S-bupropion had a higher CL int of formation than the corresponding diastereoisomer derived from R-bupropion. Figure 6 summarizes the fractional clearance (f m, racemic ) that each metabolite contributes to the clearance of racemic bupropion. In human liver microsomes, S,S-threohydrobupropion was found to be the major metabolite, contributing 37% to the total racemic bupropion clearance.
Characterization of Bupropion Metabolism in Marmoset Monkey Liver Microsomes (MMLMs)
In MMLMs, the total CL int of S-bupropion was 1.3-fold greater than that of R-bupropion ( Table 2) . As with HLMs, R,R-hydroxybupropion was found to be the major metabolite of R-bupropion; however, unlike HLMs, in which S,S-threohydrobupropion was the major metabolite derived from S-bupropion, S,S-hydroxybupropion was the major metabolite in MMLMs. The formation clearance (CL int ) of S,S-hydroxybupropion was similar to that of R,R-hydroxybupropion in MMLMs. Also, the CL int of S,S-threohydrobupropion was nearly twofold higher than that of R,R-threohydrobupropion, while the CL int of R,S-erythrohydrobupropion was threefold higher than that of S,R-erythrohydrobupropion. When the three metabolites were ranked in order of contribution to the total CL int of the selected enantiomer of bupropion, the metabolite rankings were observed to be the same for both enantiomers of bupropion. In terms of the overall contribution of each of the measured metabolites to the total racemic bupropion clearance (Fig. 6) , R,R-hydroxybupropion was the major metabolite, contributing 36% to the overall bupropion clearance (0.71/2). The rankings of the R-bupropion-derived metabolites in terms of their formation kinetics (f m,enantiomer ) was the same for both HLMs and MMLMs. However, the rankings of the S-bupropion-derived metabolites in terms of their formation kinetics were different for the two species, with f m,enantiomer of S,S-hydroxybupropion being threefold higher, S,S-threohydrobupropion threefold lower, and R,S-erythrohydrobupropion 3.5-fold higher in MMLMs than in HLMs. Values expressed represent the mean ± SE of the estimate 
BP bupropion, R,R-OHBP R,R-hydroxybupropion, R,R-ThreoBP R,R-threohydrobupropion, S,R-ErythroBP S,R-erythrohydrobupropion, S,S-OHBP S,S-hydroxybupropion, S,S-ThreoBP S,S-threohydrobupropion, R,S-ErythroBP R,S-erythrohydrobupropion
Species Substrate Metabolite V max (pmol/min/mg microsomal protein) K m (µM) CL int (V max /K m ) (µl/
Characterization of Bupropion Metabolism in Rat Liver Microsomes (RLMs)
In striking contrast to HLMs and MMLMs, the total CL int of S-bupropion in RLMs was sevenfold lower than that of R-bupropion (Table 3) , and the erythrohydrobupropion isomers were the dominant metabolites of both R-and S-bupropion. While the formation kinetics of R,R-hydroxybupropion, R,Rthreohydrobupropion, and S,S-hydroxybupropion were linear, those of S,R-erythrohydrobupropion, R,S-erythrohydrobupropion, and S,S-threohydrobupropion followed Michaelis-Menten kinetics (Fig. 4) . In terms of the relative contributions of all the measured metabolites to racemic bupropion clearance, S,Rerythrohydrobupropion was the chief metabolite, contributing 44% to the overall bupropion clearance (Fig. 6) . In comparison to HLMs, f m,enantiomer of R,R-hydroxybupropion in RLMs was fivefold lower, that of R,R-threohydrobupropion was 31-fold lower, and that of S,R-erythrohydrobupropion was sevenfold higher in RLMs. The f m,enantiomer of S,S-hydroxybupropion was nearly the same in both RLMs and HLMs, whereas it was twofold lower for S,S-threohydrobupropion and sevenfold higher for R,S-erythrohydrobupropion in RLMs.
Characterization of Bupropion Metabolism in Mouse Liver Microsomes (MLMs)
In MLMs, the total CL int of S-bupropion was nearly twofold lower than that of R-bupropion (Table 4) . As in rats, but not humans, the total R-bupropion CL int was faster than the total S-bupropion CL int . R,R-hydroxybupropion was responsible for 95% of the total R-bupropion clearance; likewise, S,Shydroxybupropion was the main metabolite from S-bupropion phase I metabolism (f m,enantiomer = 95%). Among all the measured metabolites, S,S-and R,R-hydroxybupropion were both found to contribute 48% towards total racemic bupropion clearance (Fig. 6) . Upon comparing the contributions of the metabolites to the CL int, H for each enantiomer (f m,enantiomer ), it was observed that R,R-hydroxybupropion formation was twofold higher, R,R-threohydrobupropion was eightfold lower, and that of S,R-erythrohydrobupropion was 13-fold lower in MLMs than in HLMs. The f m,enantiomer of S,S-hydroxybupropion in MLMs was fivefold higher, that of S,S-threohydrobupropion was 38-fold lower, and that of R,Serythrohydrobupropion was twofold lower than in HLMs.
As summarized in Fig. 6 , comparing across the four species, the total contribution of hydroxybupropion to the racemic bupropion clearance was highest in mouse (96%), followed by monkey (62%) and human (38%), and was lowest in rat (17%). Threohydrobupropion was the most prevalent metabolite in human microsomes (53%); its percentages for the other species were: 23% in monkey, 17% in rat, and 3% in mouse. The highest fraction of total erythrohydrobupropion was observed in rat (66%), followed by monkey (14%) and human (9%), and the lowest fraction was observed in mouse liver microsomes (1.3%). 
. R,R-OHBP R,R-hydroxybupropion, R,R-ThreoBP R,R-threohydrobupropion, S,R-ErythroBP S,R-erythrohydrobupropion. S,S-OHBP S,S-hydroxybupropion, S,S-ThreoBP S,S-threohydrobupropion, R,S-ErythroBP R,S-erythrohydrobupropion
Discussion
The objective of the study reported herein was to compare phase I metabolite formation kinetics in rodents and NHPs to those in human, in order to identify an appropriate species to employ in studies of stereospecific bupropion disposition in the CNS. This is an essential stepping stone towards building a translational pharmacokinetic-pharmacodynamic model that can further our understanding of the variability in response to bupropion and the sources of variability.
The 5.6-fold higher total CL int of S-bupropion relative to R-bupropion in HLMs is close to the fivefold difference observed in human liver S9 fractions [28] . This preferential loss of S-bupropion observed in two in vitro studies agrees with clinical results [21] identifying S-bupropion as the higher clearance enantiomer. The difference between the CL int values for R,R-and S,S-hydroxybupropion in HLMs reported here (0.48 versus 0.93 µl/min/mg of microsomal protein, respectively) is in excellent agreement with the corresponding difference reported in a human liver S9 fraction (0.47 versus 0.81 µl/min/mg of S9 protein, respectively) [28] . This agreement confirms that hydroxybupropion is primarily formed by microsomal enzymes [23, 28, 30, 57] . For both diastereomers, CYP2B6 was shown to be responsible for 90% of their formation, with minor contributions from CYP2C19 and CYP3A4 [28] . The linear formation rates observed for these two metabolites over the concentration range evaluated are also consistent with the estimated CYP2B6 K m values of > 100 µM for R-and S-bupropion [28] . The disparity in the CL int values for R,R-and S,Sthreohydrobupropion formation between HLMs (0.27 µL/ min/mg and 3.59 µL/min/mg protein, respectively) and the S9 fraction (0.69 µL/min/mg and 5.61 µL/min/mg protein, respectively) [28] is attributed to the cytoplasmic aldo-keto reductase contribution in the S9 fraction [30, 57] . The CL int values of S,R-and R,S-erythrohydrobupropion (0.11 µl/ min/mg and 0.29 µl/min/mg of microsomal protein, respectively) observed in our study are in close agreement with their values (0.11 µl/min/mg and 0.25 µl/min/mg of S9 protein, respectively) in liver S9, as reported in [28] . As with hydroxybupropion, this similarity supports the notion that microsomal 11β-HSD1 is primarily responsible for the production of erythrohydrobupropion diastereoisomers at clinically relevant bupropion concentrations [21] . It is also consistent with reports of a minor contribution from cytosolic aldo-keto reductase to the formation of total erythrohydrobupropion [30, 57] . Overall, the finding that racemic bupropion clearance in HLMs occurs mainly through carbonyl reduction (62% combined for threo-and erythrohydrobupropion isomers, as summarized in Fig. 6 ) is consistent with published in vitro and in vivo results [13, 20, 21, 28, 30, 50, 57] .
The contribution of phase I metabolites to observed pharmacologic effects is unclear from the results of studies based on rats and mice [24-27, 29, 38, 39, 49, 50, 58] . In part, this is due to the different metabolic profiles of rats and mice. Our finding of higher hydroxybupropion formation in MLMs than in RLMs is consistent with the higher systemic exposure to this metabolite in vivo in mice [24, 27, 49] . S,S-hydroxybupropion is an active metabolite, possessing a potency comparable to that of bupropion at the dopamine active transporter (DAT), norepinephrine transporter (NET), and nicotinic receptor [25, 26, 33] . Combined, these pharmacokinetic and pharmacologic data provide the basis for speculation for the superior translational efficacy of mice as compared to humans [24-26, 29, 39, 49] . However, our findings (summarized in Fig. 6 ) that threohydrobupropion diastereoisomers account for < 5% of the racemic bupropion clearance in MLMs versus 54% in HLMs and that threohydrobupropion possesses exposure-related pharmacologic or toxic activity [29, 33, 39] limit the translational value of the mouse from the standpoint of safety.
Based simply on the close genetic homology of NHPs to humans [59] , it is reasonable to expect they would be a superior translational model to understand bupropion CNS disposition and ensuing central effects in humans. However, data on the kinetics of its metabolites in vitro and on the disposition of those metabolites in vivo in NHPs are limited [51, [60] [61] [62] , and reports of stereoselective analysis are absent. We found that the total percentages of hydroxybupropion, threohydrobupropion, and erythrohydrobupropion in marmoset monkey liver microsomes (62%, 23%, and 14%, respectively) are in good agreement with the corresponding values in a previously published report (62%, 28%, 10%) on baboon hepatic microsomes [60] . Of note, the Wang et al. [60] study identified that the CYP2B subfamily was responsible for hydroxybupropion formation in baboons, which is also the case in humans, supporting the idea that bupropion metabolism is similar in NHPs and humans. However, the Wang et al. [60] study did not delineate the contributions of the diastereomer metabolites, and it is important to determine these both systemically and centrally in order to more fully comprehend the complex CNS pharmacology of bupropion. Despite marked differences in bupropion metabolism between rodents and humans, in vivo studies in rodents have identified an important contribution of phase I metabolites to the effects of bupropion [24, 26, 29, 33, 49] . Rodent studies also provide evidence that the metabolite-to-bupropion exposure ratio in the brain is different from that in plasma [24] . Potential reasons for this could be different permeability properties of the metabolites relative to bupropion [48] and/or bupropion metabolism in the brain [63] . Overall, given the relative similarity we observed between MMLMs and HLMs in stereoselective bupropion phase I metabolism, systemic and brain disposition studies conducted in NHPs in vivo would be preferable to rodent studies for developing translational physiologic-based pharmacokinetic models to improve our understanding of bupropion CNS pharmacology, including its potential to elicit seizures, in the context of its complex metabolic disposition.
A limitation of our analysis is that we did not measure blood-to-plasma concentration ratios of the two enantiomers in the four species; nor did we measure the unbound plasma fractions (f u ) of these enantiomers in the four species. These determinations would have enabled the hepatic blood clearances of the two enantiomers to be determined in each species, which would have provided a more comprehensive comparison. However, Sager et al. [28] , who did estimate plasma binding and blood-plasma concentration ratios for the two enantiomers, indicated that differences in hepatic extraction alone were sufficient to explain the stereoselective disposition of bupropion. We invoke this argument for the other species too [64] . Also, the racemic bupropion f u in rats ranges from 0.31 to 0.49 [64] , which is close to the range seen in humans [28, 64] , so they are considered to be similar.
Conclusion
This study used hepatic microsomes as a tool to compare humans with three animal species in terms of the stereospecific formation kinetics of bupropion metabolites. To our knowledge, this is the first characterization of the stereoselective metabolism of bupropion in rodent and NHP liver microsomes. Our findings demonstrate that phase I metabolism in NHPs best approximates that observed in humans, thereby supporting-based only on the similarity between NHPs and humans in their stereoselective metabolite formation patterns-the preferential use of NHPs to extend our understanding of stereoselective bupropion CNS disposition in humans. For example, gaining insight into carriermediated transport at the BBB and/or metabolism within the brain would bring us closer to elucidating the reasons for the unpredictable adverse effects of this drug on the CNS.
